[Guidelines for assessment of patients with connective tissue diseases].
Guidelines for assessments of connective tissue diseases in social jurisdiction and for insurance are not available in Germany. This article is a guideline reflecting published data, modern therapy and actual prognosis. In addition, help for interpretation and examples are given.
Sander
O
O
Rheumazentrum Düsseldorf, Klinik für Nephrologie und Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany. Sander@rheumanet.org
Fischer-Betz
R
R
Schneider
M
M
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D003240:Connective Tissue Diseases / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy; D019091:Critical Pathways; D004185:Disability Evaluation; D004608:Eligibility Determination / Q000331:legislation & jurisprudence; D005104:Expert Testimony / Q000331:legislation & jurisprudence*; D005260:Female; D005858:Germany; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D008180:Lupus Erythematosus, Systemic / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010348:Patient Care Team / Q000331:legislation & jurisprudence*; D011379:Prognosis; D012050:Rehabilitation, Vocational; D012943:Social Security / Q000331:legislation & jurisprudence; D013256:Steroids; D014938:Work Capacity Evaluation
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents; D013256:Steroids